Can Plus Therapeutics Inc. turn REYOBIQ into a differentiated platform for difficult-to-treat CNS cancers?
Can REYOBIQ change CNS cancer treatment? Discover why Plus Therapeutics Inc.’s latest leptomeningeal metastases data is drawing attention.
What Eric J. Daniels’ appointment means for Plus Therapeutics and its CNS oncology pipeline
Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.
Plus Therapeutics reimbursement push gains traction as AMA grants CNSide a dedicated PLA code
Plus Therapeutics has won an AMA PLA code for CNSide. Read why this reimbursement milestone could shape adoption, coverage, and diagnostic growth.